Drug Trial News RSS Feed - Drug Trial News

BirchBioMed announces successful completion of Phase I trial for topical treatment to prevent scarring

BirchBioMed announces successful completion of Phase I trial for topical treatment to prevent scarring

BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial. [More]
Fiocruz to start phase II clinical trials of novel vaccine for schistosomiasis

Fiocruz to start phase II clinical trials of novel vaccine for schistosomiasis

The Oswaldo Cruz Foundation at Rio de Janeiro, Brazil, will start the phase II clinical trials of a vaccine for schistosomiasis, called 'Sm14 Vaccine'. [More]
Anesthetic administered with nasal spray effective in preventing pain during dental treatment

Anesthetic administered with nasal spray effective in preventing pain during dental treatment

A fear of pain causes many people with dental phobias to avoid or delay needed treatment. In some cases, the injection of a numbing agent can be the most painful part of the visit. [More]
SSRI treatment improves cognitive and social functioning in young children with fragile X

SSRI treatment improves cognitive and social functioning in young children with fragile X

Treatment with sertraline may provide nominal but important improvements in cognition and social participation in very young children with fragile X syndrome, the most common genetic cause of intellectual disability and the leading single-gene cause of autism, a study by researchers with the UC Davis MIND Institute has found. [More]
Three like-minded nonprofits collaborate to launch immunotherapy clinical trial for pediatric brain tumors

Three like-minded nonprofits collaborate to launch immunotherapy clinical trial for pediatric brain tumors

A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors. [More]
New clinical trial to examine safety of checkpoint inhibitor in pediatric cancer patients

New clinical trial to examine safety of checkpoint inhibitor in pediatric cancer patients

In an innovative, first-in-pediatrics study, available only at Children's Hospital Los Angeles, researchers will be enrolling children between 1 and 18 years of age who have certain types of relapsed or treatment-resistant cancer. [More]
BCL-2 inhibitor shows promise in AML patients

BCL-2 inhibitor shows promise in AML patients

Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data. [More]
CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

Cancer Treatment Centers of America at Western Regional Medical Center has dosed its first three patients as part of the launch of a Phase I clinical trial using a novel antibody to treat patients with advanced solid tumors. [More]
Study demonstrates significant reduction in severity of exercise-induced asthma following B-GOS consumption

Study demonstrates significant reduction in severity of exercise-induced asthma following B-GOS consumption

Clasado Biosciences Limited, the producers and suppliers of Bimuno(R) (B-GOS), a unique patented trans-galactooligosaccharide complex, today announces the publication of results for the latest clinical study using B-GOS. [More]
NIH launches clinical trial of experimental vaccine candidate for preventing Zika virus infection

NIH launches clinical trial of experimental vaccine candidate for preventing Zika virus infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection. [More]
Combination therapy shows no better benefits than placebo for patients with knee osteoarthritis

Combination therapy shows no better benefits than placebo for patients with knee osteoarthritis

Chondroitin sulfate (CS) plus glucosamine sulfate (GS) was no better than placebo for reducing pain and function impairment in a multicenter, randomized, double-blinded, placebo-controlled study of 164 patients with knee osteoarthritis. [More]
NIAID begins early-stage trial of experimental vaccine for preventing yellow fever virus

NIAID begins early-stage trial of experimental vaccine for preventing yellow fever virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus. [More]
Duke to lead early-stage clinical trials for promising new neurological therapies

Duke to lead early-stage clinical trials for promising new neurological therapies

Duke University could receive up to $19 million to lead early-stage clinical trials for new drugs to treat neurological conditions such as Alzheimer's disease and neuropathy. [More]
Pulmatrix announces positive results from Phase 1 study of novel dry powder formulation in COPD patients

Pulmatrix announces positive results from Phase 1 study of novel dry powder formulation in COPD patients

Pulmatrix, Inc., today announced positive topline data from a Phase 1 pilot pharmacokinetic bioavailability trial of PUR0200. PUR0200 is a novel dry powder formulation of a currently marketed once daily bronchodilator, formulated in the company's proprietary iSPERSETM dry powder delivery technology. [More]
Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer. [More]
Study highlights effectiveness of atypical antipsychotic drug in treating children with TD

Study highlights effectiveness of atypical antipsychotic drug in treating children with TD

A meta-analysis of clinical trials evaluating the effectiveness of aripiprazole for the treatment of Tourette's disorder (TD) in children and adolescents showed a significantly greater overall improvement in total tics and tic severity from pretreatment to post-treatment for the aripiprazole compared to the placebo group. [More]
Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Five-year survival data published online today in Blood, the Journal of the American Society of Hematology, suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies. [More]
Phase III clinical study of promising prostate cancer drug reveals surprising results

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment. [More]
Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson's disease or dementia with Lewy bodies. [More]
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met. [More]
Advertisement
Advertisement